|本期目录/Table of Contents|

[1]宋学武,高慧儿,张飞雨,等.CYP3A4多态性对活体肝移植患儿术后早期他克莫司浓度/剂量比和个体内变异度的影响[J].天津医科大学学报,2021,27(04):388-391.
　SONG Xue-wu,GAO Hui-er,ZHANG Fei-yu,et al.Effect of CYP3A4 polymorphism on tacrolimus concentration to dose ratio and intra-patient variability in the early postoperative period for infant patients with living donor liver transplantation[J].Journal of Tianjin Medical University,2021,27(04):388-391.
点击复制

CYP3A4多态性对活体肝移植患儿术后早期他克莫司浓度/剂量比和个体内变异度的影响(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
27卷
期数:
2021年04期
页码:
388-391
栏目:
临床医学
出版日期:
2021-07-20

文章信息/Info

Title:
Effect of CYP3A4 polymorphism on tacrolimus concentration to dose ratio and intra-patient variability in the early postoperative period for infant patients with living donor liver transplantation
文章编号:
1006－8147（2021）04-0388-04
作者:
宋学武1; 高慧儿2; 张飞雨1; 秦寅鹏2; 张弋2
（1.天津医科大学一中心临床学院，天津 300192；2.天津市第一中心医院药学部，南开大学医学院，天津 300192）
Author(s):
SONG Xue-wu1; GAO Hui-er2; ZHANG Fei-yu1; QIN Yin-peng2; ZHANG Yi2
（1. First Central Clinical College, Tianjin Medical University, Tianjin 300192，China；2. Department of Pharmacy, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China）
关键词:
活体肝移植; 他克莫司; CYP3A4; 浓度/剂量比; 个体内变异度
Keywords:
living donor liver transplantation; tacrolimus; CYP3A4; concentration to dose ratio; intra-patient variability
分类号:
R781.4
DOI:
-
文献标志码:
A
摘要:
目的：探讨供、受者CYP3A4多态性对活体肝移植（LDLT）患儿术后1个月内他克莫司浓度/剂量比（C0/D）和个体内变异度（IPV）的影响。方法：收集77例活体肝移植患儿，化学发光免疫分析法测定他克莫司谷浓度（C0）。检测供、受者CYP3A4*18B基因型，根据患者至少携带一个CYP3A4*1基因将患者分为两组，即CYP3A4表达组（EX，CYP3A4*1/*1或CYP3A4*1/*18B）和CYP3A4非表达组（NEX，CYP3A4*18B/*18B）。分析CYP3A4*18B多态性对不同基因型患者他克莫司C0/D和IPV的影响。结果：对于供者CYP3A4多态性，CYP3A4表达组他克莫司C0/D在术后第1周（Z=-4.694，P＜0.001）、第2周（Z=-4.469，P＜0.01）和第3周（Z=-2.205，P＜0.05）均显著低于CYP3A4非表达组；对于受者CYP3A4多态性，CYP3A4表达组他克莫司C0/D在术后第1周（Z=-4.976，P＜0.001）和第2周（Z=-3.054，P＜0.01）均显著低于CYP3A4非表达组。此外，供、受者CYP3A4表达组与CYP3A4非表达组他克莫司IPV均无差异（均P>0.05）。结论：CYP3A4多态性影响LDLT患儿术后早期他克莫司C0/D，对他克莫司IPV没有影响。
Abstract:
Objective: To investigate the effectof donors′ and recipients′ CYP3A4 polymorphisms on tacrolimus concentration to dose ratio（C0/D） and intra-patient variability（IPV） within one month for infant patients with living donor liver transplantation（LDLT）. Methods: A total of 77 infant patients with LDLT were collected. Tacrolimus trough concentration（C0） was determined by chemiluminescent microparticle immunoassay.The donors′ and recipients′ CYP3A4*18B genotypes were detected.According to individuals with at least one CYP3A4*1 allele，patients were divided into two groups including CYP3A4 expressers（EX，CYP3A4*1/*1 or CYP3A4*1/*18B） and CYP3A4 non-expressers（NEX，CYP3A4*18B/*18B）.The effect of CYP3A4*18B polymorphism on tacrolimus C0/D and IPV in patients with different genotypes was analyzed. Results: For the donors′ CYP3A4 polymorphism，tacrolimus C0/D in CYP3A4 expressers was significantly lower than that in CYP3A4 non-expressers in the first week（Z=-4.694，P＜0.001），second week（Z=-4.469，P＜0.01），and third week（Z=-2.205，P＜0.05） after transplantation. For the recipients′ CYP3A4 polymorphism, tacrolimus C0/D in CYP3A4 expressers was significantly lower than that in CYP3A4 non-expressers in the first week（Z=-4.976，P＜0.001） and second week（Z=-3.054，P＜0.01） after transplantation. In addition, there was no difference in tacrolimus IPV between CYP3A4 expressers and CYP3A4 non-expressers（all P>0.05）. Conclusion: The CYP3A4 polymorphism has an effect on tacrolimus C0/D for infant patients with LDLT in the early postoperative period，but has no effect on tacrolimus IPV.

参考文献/References:

[1] Brunet M，Van Gelder T，?魡sberg A， et al.Therapeutic drug monitoring of tacrolimus-personalized therapy：second consensus report[J].Ther Drug Monit，2019，41（3）：261
[2] Shuker N，Shuker L，VanRosmalen J，et al.A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation[J].Transpl Int，2016，29（11）：1158
[3] Musuamba F T，Guy-Viterbo V，Reding R，et al.Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation[J].Ther Drug Monit，2014，36（1）：54
[4] Kasahara M，Sakamoto S，Sasaki K，et al.Living donor liver transplantation during the first 3 months of life[J].Liver Transpl，2017， 23（8）：1051
[5] Liu B Y，Chen W Q，Chen Z G，et al.The effects of CYP3A5 genetic polymorphisms on serum tacrolimus dose-adjusted concentrations and long-term prognosis in Chinese heart transplantation recipients[J]. Eur J Drug Metab Pharmacokinet，2019，44（6）：771
[6] Pashaee N，Bouamar R，Hesselink D，et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance[J]. Ther Drug Monit，2011，33（3）：369
[7] Nadalin S，Capobianco I，Panaro F， et al. Living donor liver transplantation in Europe[J].Hepatobiliary Surg Nutr，2016，5（2）：159
[8] Cuenca A G，Kim H B，VakiliK.Pediatric liver transplantation[J].Semin Pediatr Surg，2017，26（4）：217
[9] 中华医学会器官移植学分会， 中国医师协会器官移植医师分会. 中国儿童肝移植临床诊疗指南（2015版）[J]. 临床肝胆病杂志， 2016，32（7）：1235
[10] Birdwell K A，Decker B，Barbarino J M， et al.Clinical pharmacogenetics implementation consortium（CPIC） guidelines for CYP3A5 genotype and tacrolimus dosing[J].Clin Pharmacol Ther，2015， 98（1）：19
[11] Ji E，Choi L，Suh K S， et al.Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation[J].Transplantation，2012，94（8）：866
[12] Hendijani F，Azarpira N，Kaviani M. Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation：a systematic review and meta-analysis[J].Clin Transplant，2018，32（8）：e13306
[13] Lloberas N，Elens L，Llaudó I， et al.The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation[J].Pharmacogenet Genomics，2017，27（9）：313
[14] Abdel-Kahaar E，Winter S，Tremmel R，et al.The impact of CYP3A4*22 on tacrolimus pharmacokinetics and outcome in clinical practice at a single kidney transplant center[J].Front Genet，2019，10：871
[15] Werk A N，Cascorbi I. Functional gene variants of CYP3A4[J].ClinPharmacol Ther，2014，96（3）：340
[16] 朱琳，宋洪涛，王庆华，等.CYP3A4*18B和CYP3A5*3基因多态性对肾移植患者他克莫司剂量及浓度的影响[J].药学学报，2012，47（7）：878
[17] Tamashiro E Y，Felipe C R，Genvigir F， et al.Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients[J].Drug Metab Pers Ther，2017，
32（2）：89
[18] Gijsen V，Mital S，Van Schaik R H， et al.Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients[J]. J Heart Lung Transplant，2011，30（12）：1352
[19] Przepiorka D，Blamble D，Hilsenbeck S， et al.Tacrolimus clearance is age-dependent within the pediatric population[J].Bone Marrow Transplant，2000，26（6）：601
[20] Cheung C Y，Chan K M，Wong Y T， et al.Impact of CYP3A5 genetic polymorphism on intrapatient variability of tacrolimus exposure in Chinese kidney transplant recipients[J].Transplant Proc，2019， 51（6）：1754

相似文献/References:

[1]薛志杰综述,王荔,杨虎,等.特发性膜性肾病的临床治疗进展[J].天津医科大学学报,2022,28(03):336.

备注/Memo

备注/Memo:
基金项目：白求恩·医学科学研究基金项目（TA201933）；天津市卫生健康科技项目（KJ20226）
作者简介：宋学武(1995-)，男，硕士在读，研究方向：临床药学；通信作者：张弋，E-mail: wing_zh1821@sina.com。
更新日期/Last Update: 2021-07-25